Drug Search Results
More Filters [+]

ZSP-1602

Alternative Names: zsp-1602, zsp1602, zsp 1602
Latest Update: 2020-07-22
Latest Update Note: Clinical Trial Update

Product Description

Zhongsheng Pharmaceutical is developing zsp-1602, an Oral SMO Inhibitor for basal cell carcinoma, adenocarcinoma of esophagogastric junction, small cell lung cancer, neuroendocrine neoplasm and other advanced solid tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03734913)

Mechanisms of Action: SMO Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ZSP-1602

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Neuroendocrine Tumors|Medulloblastoma|Basal Cell Carcinoma|Small Cell Lung Cancer|Esophageal Cancer|Glioblastoma|Gastrointestinal Cancer|Neuroendocrine Carcinoma|Adenocarcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ZSP1602-16-01

P1

Unknown status

Medulloblastoma|Basal Cell Carcinoma|Gastrointestinal Cancer|Small Cell Lung Cancer|Adenocarcinoma|Esophageal Cancer|Neuroendocrine Tumors|Glioblastoma|Neuroendocrine Carcinoma

2021-07-31

41%

CTR20181036

P1

Unknown Status

Neuroendocrine Tumors|Medulloblastoma|Basal Cell Carcinoma|Small Cell Lung Cancer|Esophageal Cancer|Glioblastoma|Gastrointestinal Cancer|Neuroendocrine Carcinoma

None

Recent News Events

Date

Type

Title